10-Q quarterly report · filed Nov 13, 2026

Inhibrx Biosciences, Inc. (INBX) Q3 2026 10-Q Quarterly Report

Short answer

Inhibrx Biosciences, Inc. (INBX) filed its Q3 2026 10-Q quarterly report on Nov 13, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $2M with net income of −$39M.

Q3 2026 key financials · XBRL

Revenue
$2M
Net income
−$39M
−9.9% YoY · −5.7% QoQ
Operating margin
-1586.8%
EPS (diluted)
−$2.46
−7.9% YoY · −5.1% QoQ

Source: XBRL data from the Inhibrx Biosciences, Inc. (INBX) Q3 2026 10-Q on SEC EDGAR. USD.

Inhibrx Biosciences, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $2.0M, versus $0 in Q3 2025, entirely from Pfizer license fee revenue
  • Net loss $38.7M versus $35.3M, operating loss $31.7M versus $33.8M
  • R&D expense $26.0M, down 9% YoY, while G&A rose to $7.8M from $5.3M
  • Cash $199.5M at September 30, 2026, with $177.8M financing inflows including $175.0M debt proceeds
  • Outlook: cash sufficient for at least 12 months, but continued losses and higher clinical, manufacturing, and pre-commercialization spending expected

Risk Factors

  • Newly added regulatory risk: BIOSECURE Act restricts U.S. government dealings involving designated biotechnology companies of concern
  • Most materially updated manufacturing risk: FDA Form 483 observations at both ozekibart contract manufacturers threaten BLA approval
  • Clinical risk: Ozekibart BLA may face a Complete Response Letter if manufacturers fail to resolve inspection findings
  • Operational risk: Limited third-party manufacturers and no long-term supply agreements increase supply disruption exposure
  • Market risk: Unbuilt commercialization infrastructure could impair ozekibart launch execution and reimbursement uptake

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Inhibrx Biosciences, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.